En Es
Categories

Industry News

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

By Labmedica International staff writers
13 Apr 2021

Image: The Luminex Aries® System (Photo courtesy of Luminex Corporation)DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.

Luminex develops, manufactures and sells proprietary biological testing technologies and products with leading applications throughout the Diagnostics and Life Science industries. Luminex is a leader in multiplexing technology, one of the fastest growing markets in the molecular space, with more than 900 active clients. With its first-class technology and extensive Life Science solutions supporting clinical and pharmaceutical research and development, Luminex is highly complementary to DiaSorin's growing diagnostics segment.

The acquisition will broaden DiaSorin's positioning in the molecular diagnostics space and strengthen its existing value proposition in line with its strategic priorities. Through the acquisition, DiaSorin will gain access to Luminex's molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the US. The acquisition will also provide access to Luminex's applications throughout the Life Science industry, supporting access to academic and scientific research to shape market intelligence on future market trends, engaging with biopharma companies to drive opportunities for long-term partnerships (e.g. vaccine development, biological drugs) and access to clinical multiplexing assays for future Value Based Care projects based on diagnostic algorithms.

"Luminex perfectly fits with our strategy to grow our positioning in the molecular diagnostics space, to broaden our presence in the US, and to create additional value through Life Science offerings," said Carlo Rosa, CEO of DiaSorin Group. "Together, DiaSorin and Luminex will provide a unique offer to laboratories, researchers, clinicians and patients worldwide, matching our extensive solutions in immunodiagnostics and molecular diagnostics with Luminex's outstanding expertise in multiplexing technology and recognized leadership in life science applications."

"The combined company should provide new opportunities for our employees within a larger company that is poised to become a strong leader in the molecular diagnostics and life sciences space, and I want to thank all of our employees, customers, and partners for their contributions over our 25+ year history," said Nachum "Homi" Shamir, Chairman, President and CEO of Luminex.


Related Links:
DiaSorin S.p.A.
Luminex Corporation




E-mail Print
FaceBook Twitter Google+ Linked in

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
More info

More articles about Luminex Corporation

16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More

Additional news

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
17 Sep 2021
44th IHF World Hospital Congress Presents Over 60 Plenary Sessions and 200 Renowned Speakers Across Four-Day Event
The 44th World Hospital Congress organized by The International Hospital Federation (Geneva, Switzerland) will bring together more than 200 healthcare experts, leading industry thinkers, and best practice presenters at over 60 sessions around nursing leadership, humanizing technology, COVID-19 vaccination, the next global pandemic, etc.
Read More
17 Sep 2021
Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028
 The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising infectious diseases, technological developments, as well as increased knowledge and acceptance of tailored treatments.
Read More
15 Sep 2021
Certest Offers Sensitive, Useful and Cheap CE-IVD Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.
Read More
15 Sep 2021
Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience
Mesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).
Read More
14 Sep 2021
Zoll Acquires Medical Device and Digital Health Company Itamar Medical
ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has signed an agreement to acquire Itamar Medical Ltd. (Caesarea, Israel), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway.
Read More
13 Sep 2021
Global Blood, Gas and Electrolyte Analyzers Market Projected to Reach Nearly USD 3.50 Billion by 2023
The global blood, gas and electrolyte analyzers market is projected to grow at a CAGR of 8.6% from more than USD 2.10 billion in 2016 to nearly USD 3.50 billion by the end of 2023, driven by rapid developments in the healthcare sector that are resulting in the implementation of technologies to help care providers and patients in treating diseases. For instance, hospitals are implementing technologies like AR and VR that can provide real-time simulation of human body that can help them understand the anomaly of patients. However, the need for blood, gas analyzers to achieve greater accuracy and the requirement of regular maintenance are expected to hinder market growth.
Read More
09 Sep 2021
Stryker Completes Acquisition of Medical Device Company Gauss Surgical
Stryker (Kalamazoo, MI, USA) has completed the acquisition of Gauss Surgical (Menlo Park, CA, USA), a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery.
Read More
08 Sep 2021
Global In Vitro Diagnostics (IVD) Quality Control Market Projected to Reach USD 1.4 Billion by 2026
The global in vitro diagnostics (IVD) quality control market is projected to grow at a CAGR of 5.3% from USD 1.1 billion in 2021 to USD 1.4 billion by 2026, thanks to the significant role played by IVD testing in clinical decision-making.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions